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Human pluripotent stem cell (hPSC) lines exhibit
repeated patterns of genetic variation, which can
alter in vitro properties aswell as suitability for clinical
use. We examined associations between copy-num-
ber variations (CNVs) on chromosome 17 and hPSC
mesodiencephalic dopaminergic (mDA) differentia-
tion. Among 24 hPSC lines, two karyotypically normal
lines, BG03 and CT3, and BG01V2, with trisomy 17,
exhibited amplification of the WNT3/WNT9B region
and rapid mDA differentiation. In hPSC lines with
amplifiedWNT3/WNT9B, basic fibroblast growth fac-
tor (bFGF) signaling through mitogen-activated pro-
tein kinase (MAPK)/ERK amplifies canonical WNT
signaling by phosphorylating LRP6, resulting in
enhanced undifferentiated proliferation. When bFGF
is absent, noncanonical WNT signaling becomes
dominant due to upregulation of SIAH2, enhancing
JNK signaling and promoting loss of pluripotency.
When bFGF is present during mDA differentiation,
stabilization of canonical WNT signaling causes up-
regulation of LMX1A and mDA induction. Therefore,
CNVs in 17q21.31, a ‘‘hot spot’’ for genetic variation,
have multiple and complex effects on hPSC cellular
phenotype.INTRODUCTION
While copy-number variations (CNVs) make major contributions
to human genetic variation (Zhang et al., 2009), there have been
few opportunities to examine their roles in altered cellular func-
tion and development. We have taken advantage of variations
in differentiation capacity between a series of human pluripotent
stem cell (hPSC) lines, including BG01V2 with trisomy 17, to
explore the role of chromosome 17 CNVs in mesodiencephalic
dopaminergic (mDA) neuronal differentiation.616 Cell Reports 10, 616–632, February 3, 2015 ª2015 The AuthorsThe utility of both human embryonic stem cells (hESCs) and
human induced pluripotent stem cells (hiPSCs) depends on dif-
ferentiation to specific somatic cell types. Clinical applications
include transplantation to replace or restore the mDA neurons
lost in Parkinson’s disease. hPSC lines differ in features that
include growth in the undifferentiated state (Werbowetski-Ogilvie
et al., 2009), potential for tumor formation (Ben-David and Ben-
venisty, 2011), and differentiation to selected phenotypes (Kim
et al., 2011). These factors impact the utility of hPSCs both for
transplantation and as models of human cell types and organ
systems for in vitro studies of development and drug discovery.
Parallels between hPSC cytogenetic changes and neoplastic
progression (Werbowetski-Ogilvie et al., 2009) emphasize the
need for genetic analyses of hPSCs. The genomes of many indi-
vidual humans contain CNVs that span between a few hundred
to more than a million bases (McCarroll et al., 2008). CNVs are
found frequently in hESCs as well as hiPSCs (Na¨rva¨ et al.,
2010) and have the potential to impact hPSC function.
The present study focused on functional characterization of
CNVs on chromosome 17. Chromosome 17 has been implicated
in pluripotency of hESCs (Ben-Yehudah et al., 2010). Gain of
chromosome 17, especially 17q, has been repeatedly observed
in hESC lines (Baker et al., 2007). Previous studies have corre-
lated genetic alterations on 17q21.31 with neurobehavioral and
neurodegenerative disorders, including mDA-related disorders
such as Parkinson’s disease (Grisart et al., 2009; Spencer
et al., 2011). We have therefore sought evidence for involvement
of chromosome 17 in variations between hPSC lines. We report
that variations in the 17q21.31-17q21.32 region that include the
WNT3-WNT9B gene cluster alter hPSC proliferation and mDA
differentiation phenotypes.
RESULTS
BG01V2 and BG03 Display Enhanced Undifferentiated
Proliferation in the Presence of Basic Fibroblast Growth
Factor and Increased Loss of Pluripotency following
Growth Factor Withdrawal
We characterized five karyotypically normal hESC lines: BG01,
BG02, BG03, ES02, and ES04, as well as BG01V2, a line with
a trisomy 17 (Vazin et al., 2008) (Figures 1A and S1A). BG01V2
was studied at two passage levels (>24 passages apart) to pro-
vide a test for genomic stability. Undifferentiated colonies of all
hESC lines displayed well-defined boundaries when cultured in
a feeder-dependent or feeder-independent manner (Figures
1B, S1B, and S1D), a feature normally absent in transformed
hESCs (Werbowetski-Ogilvie et al., 2009). All undifferentiated
lines expressed the pluripotency markers OCT3/4, SSEA4, and
NANOG (Figures 1C, S1C, and S1E; NANOG not shown). More
than 90% of cells expressed OCT3/4 (Figures 1D and S1F).
There were no significant differences in OCT3/4 or NANOG
expression (Figures 1E and S1G).
Cumulative growth curves over 6 days showed a 4-fold in-
crease in BG01V2 cell number at both early and late passages
(BG01V2-E and –L, respectively) and a 2-fold increase in
BG03, as compared to the other lines (Figure 1F). These data
are consistent with increased percentages of OCT3/4+ cells
labeled by bromodeoxyuridine (BrdU; 10 mM, 1 hr exposure at
the end of 6 days culture) in BG01V2 (-E and -L) and BG03 (Fig-
ures 1G, 1H, and S1H). Expression of the apoptotic marker An-
nexin V in OCT3/4+ cells indicated that preferential cell death
was not responsible for these differences in cell accretion (Fig-
ures S1J and S1K). Thus, BG01V2 and BG03 proliferate faster
than the remaining lines.
Following withdrawal of basic fibroblast growth factor (bFGF),
essential for maintaining pluripotency, BG01V2 (-E and -L), and
to a lesser degree BG03 lost pluripotency more rapidly than
the other cell lines (Figures 1I, 1J, and S1I).OCT3/4 and NANOG
expression also decreased more rapidly over 6 days in BG01V2
(-E and –L) and in BG03 (Figure 1K). These data suggest that an
enhanced propensity for departure from pluripotency distin-
guishes BG01V2 (-E and -L) and BG03 from the characteristic
in vitro behavior of transformed or tumorigenic hESC variants
(Werbowetski-Ogilvie et al., 2009), despite their increased rates
of proliferation.
BG01V2 and BG03 Exhibit Enhanced mDA
Differentiation
We compared mDA differentiation using a well-established pro-
tocol (Yan et al., 2005) that employs midbrain trophic factors
to generate mDA neurons via distinct stages of differentiation
in parallel to in utero mDA development. Undifferentiated hESC
colonies were converted to embryoid bodies (EBs), then differ-
entiated for 10 days in the presence of bFGF then FGF8 to yield
neuroepithelial (NE) rosettes with radially organized columnar
cells. Rosettes were isolated and cultured in the presence of
FGF8 and SHH to yield mDA progenitors (mDPs) by day 31.
These mDPs were further differentiated to reach mature mDA
neuronal identity by day 45 (Figure 2A).
At day 16, whole BG01V2 (-E and -L) and BG03 colonies dis-
played a layer of loosely arranged nestin+ cells interspersed
with nestin+ rosettes, retaining only trace areas of OCT3/4+ cells
(Figures 2B, 2C, S2A, and S2B). In other hESC lines, nestin+ ro-
setteswere restricted to the colony centers andwere surrounded
by abundant OCT3/4+ cells (Figures 2B, 2C, S2A, andS2B). Tem-
poral gene expression analysis revealed thatOCT3/4 expression
declined with concomitant increased nestin expression from day
0 to day 16 in BG01V2 (-E and -L) and BG03 (Figure 2D). TheCrapid loss of pluripotency found in BG01V2 and BG03 was thus
associated with accelerated differentiation toward a neuroecto-
dermal lineage.
We further quantified OCT3/4+ and nestin+ cells during the NE
stage. As early as day 8, there were significant disparities
between numbers of OCT3/4+ and nestin+ cells in BG01V2 (-E
and -L), BG03, and the remaining lines (Figure 2E). Surprisingly,
nestin+ cellular percentages in BG01V2 (-E and -L) declined from
days 8 to 16 (cellular percentage in BG03 started declining at
day 12), diverging from ordinary patterns observed in Figure 2D.
Percentages of TUNEL-labeled nestin+ progenitors did not
significantly increase in BG01V2 (-E and -L) or BG03 from days
8 to 16 (Figures S2C and S2D). Thus accelerated differentiation
of nestin+ cells, rather than apoptosis, seems to have been res-
ponsible this decline in nestin+ cells.
We next examined mDA differentiation. The transcription
factor LMX1A and its downstream target, MSX1, are both ex-
pressed in mDPs and required for mDA phenotype specification
(Cai et al., 2009). Both were present at day 12 in BG01V2 (-E and
-L) and at day 14 in BG03, but they appeared much later (day 31)
in the remaining lines (Figures 2F and 2G). BG01V2 (-E and -L)
displayed greater numbers of LMX1A+ rosettes per colony than
BG03 on day 16while still containing similar LMX1A+ cellular per-
centages in those rosettes (Figures 2H–2J and S2E). In nonro-
sette areas, 50% of nestin+ cells in BG01V2 (-E and -L), and
20% in BG03, differentiated to LMX1A+ cells (Figures S2F
and S2G). Thus, BG01V2 and BG03 displayed more efficient
conversion tomDPs than the remaining lines, with BG03 showing
a less efficient conversion than BG01V2.
Moreover, the neuronal marker TUJ1, the dopaminergic
marker TH, and the midbrain-specific transcription factors
NURR1 and PITX3 appeared earlier in BG01V2 (-E and -L) than
BG03 while appearing much later in the remaining lines (Figures
2F and 2G). BG01V2 (-E and -L), and to a lesser degree BG03,
showed comparable mDA differentiation at day 16 relative to
other lines at day 45 (Figures 2K–2M and S2H). Nevertheless,
all lines ultimately displayed a similar mature mDA phenotype,
manifested by high percentages of TH+ cells that expressed
NURR1 (Figures S2I and S2J). Therefore, mDA conversion was
accelerated in BG01V2 and BG03.
In contrast to LMX1A and MSX1, FOXA2, another mDP tran-
scription factor expressed in the midbrain floor plate and a
downstream target of the SHH signaling pathway (Ferri et al.,
2007), was absent from BG01V2 (-E and -L) and BG03, yet it
was present in the remaining hESC lines starting on day 31 (Fig-
ures 2F and S2K). These data indicate that LMX1A-MSX1, but
not the SHH-FOXA2 pathway, is responsible for the accelerated
mDA specification in BG01V2 and BG03. Complete mDA spec-
ification, with FOXA2 expression, in BG01V2 and BG03 could be
achieved by adding SHH from days 10 to 16 (Figure S2L).
Identification of the WNT3/WNT9B Gene Cluster at
17q21.31 in Relationship to mDA Differentiation
Next, we attempted to determine the genetic contributors to
enhanced mDA differentiation in BG01V2 and BG03. We devel-
oped an a priori list of 103 genes, including the entire WNT,
SHH, and FGF8 signaling families, that were potentially related
to mDA differentiation based on literature review (Table S1).ell Reports 10, 616–632, February 3, 2015 ª2015 The Authors 617
(legend on next page)
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We then focused on the seven genes located on chromosome 17
(Figure 3A) due to the enhanced mDA differentiation potential of
BG01V2, which contains a trisomy 17.
Principal component analysis (PCA) of hybridization intensity
data from chromosome 17 CNV and SNP probes on Affymetrix
6.0 SNP arrayswere used to search for evidence of chromosome
17 CNVs among the hESC lines. PCA of the hybridization of ma-
terial prepared from cell line DNA to CNV and SNP probes on
these arrays identified five principal components (PC1–PC5)
that contributed substantially to the overall variance among
these cell lines (Figure 3B). PC2 was strongly related to mDA dif-
ferentiation (Figures 3C and S3A). PC2 scores were significantly
lower for BG01V2 (-E and -L) and BG03 than for the remaining
lines. Mapping PC2 scores onto chromosome 17 identified loci
at 16.5–16.8 Mb, 18.2–18.5 Mb, 18.9–19.3 Mb, 31.4–31.9 Mb,
and 41.6–42.3 Mb (NCBI Build 36.3) (Figure 3D) that contributed
substantially to the overall PC2 scores. The 17q21.31, 41.6–42.3
Mb locus contains WNT3 and WNT9B, two of the seven a priori
chromosome 17 candidates for involvement with mDA differen-
tiation (Figure 3A). SNP genotyping confirmed that BG01V2 and
BG03 were not genetically related by descent (Figure S3B).
We then examined whether the DNA levels ofWNT3,WNT9B,
and NSF, which is located within the same peak as the WNT3-
WNT9B cluster (Figure 3D), varied between hESC lines. There
were increased levels of DNA for each of these genes in both
BG01V2 and BG03 (Figure 3E). By contrast, levels of DNA en-
coding the WNT receptor FZD2, also found on chromosome
17, but not located within the PC2-derived peaks, were in-
creased only in the trisomic BG01V2 line (Figures 3A and 3E).
Neither line displayed increased DNA levels for WNT1, FGF8,
or SHH (Figure 3E), which all play important roles in mDA differ-
entiation (Burbach and Smidt, 2006) but are located on chromo-
somes 12, 10, and 7, respectively.
It is generally acknowledged that there are laboratory- and cell
line-specific variations in hESCs and hiPSCs (Guenther et al.,
2010; Tomoda et al., 2012). Thus, we screened ten additional
hESC and eight hiPSC lines from various laboratories for extra
copies of WNT3/WNT9B, by using 14 probes across NSF,
WNT3, WNT9B, and GOSR2 from chromosome 17 44668035-
45018733 (NCBI Build 37.5) (Figure 3F). Two hESC lines, CT3
and SA01, showed increased levels of both WNT3 and WNT9B
DNA, while hESC lines H1 and SA02 and hiPSC line BC1 showed
increased WNT3 DNA only (Figures 3G–3I). These data support
the likelihood that genomic amplifications in the WNT3-WNT9B
region are not unusual. These genomic differences were ac-Figure 1. BG01V2 and BG03 Are Phenotypically Distinct from Other Ka
(A) Representative G-banding karyotype analysis of hESC lines. Black circle indica
(P37), and ES02 (P46).
(B) Phase-contrast images of hESC lines in feeder-dependent cultures showing
(C) Expression of OCT3/4 and SSEA4 by immunocytochemistry in each hESC lin
(D and E) Percentage of OCT3/4+ cells (D) and relative expression ofOCT3/4 andN
were expressed as fold changes with respect to BG01.
(F) Cumulative growth of hESC lines over 6 days in feeder-free culture. n = 3.
(G and H) Expression of BrdU and OCT3/4 by immunocytochemistry under feede
incorporating BrdU are shown in (H). Scale bar, 50 mm. n = 3. *p < 0.05, **p < 0.0
(I and J) Expression of OCT3/4 by immunocytochemistry (I) under feeder-free con
remaining OCT3/4+ after 6 days are shown in (J). Scale bar, 100 mm. n = 3.
(K) Relative expression in log2 form ofOCT3/4 andNANOG following bFGF withdr
Ccompanied by phenotypic differences. CT3, with complete
amplification of the WNT3-WNT9B region, exhibited enhanced
proliferation in the undifferentiated state in the presence of
bFGF, accelerated loss of pluripotency after removal of bFGF,
and highly efficient mDA induction (18.2% of cells positive for
both TUJ1 and TH in CT3 at day 16), similar to BG01V2 and
BG03 (Figures S3D–S3F).
Next, we examined expression of mRNAs encoded by the
amplified WNT genes during mDA differentiation. Because
BG01V2-E and BG01V2-L did not differ markedly, we used
BG01V2-E for further experiments. We observed greater WNT3
and WNT9B mRNA levels in BG01V2, BG03, and CT3 during
mDA differentiation, paralleling expression of these genes in
other hESC lines (Figures 3J and S3G; fold changes are shown
in Table S2). Changes in mRNA were as large as 10- to 56-
fold, greatly exceeding the corresponding changes in DNA.
WNT3 expression was predominant at the embryonic stem cell
(ES) and NE stages of differentiation, while WNT9B expression
was predominant during the EB stage. FZD2 expression was
increased in BG01V2 only, at all stages of differentiation. No dif-
ferences in expression of WNT1, FGF8 or SHH were observed
(Figures 3J and S3G). Taken together, these findings suggest
that amplification of theWNT3/WNT9B gene cluster contributes
to the acceleration of mDA differentiation seen in BG01V2,
BG03, and CT3. Expression patterns suggest distinct roles
of this increased expression at different stages of mDA
differentiation.
Canonical WNT3 and Noncanonical WNT9B Signaling
Pathways Are Activated at Different Stages of mDA
Differentiation
WNT3 and WNT9B act mainly via the b-catenin-dependent (ca-
nonical) and the Rho/JNK (noncanonical) signaling pathways,
respectively (Lie et al., 2005; Karner et al., 2009). FZD2 is involved
in both canonical and noncanonical pathways (Sato et al., 2010).
The active (dephosphorylated) form of b-catenin was elevated
during ES and NE stages for BG01V2, BG03, and CT3 as
compared to the other hESC lines and to a smaller extent at
the EB stage for BG01V2 (Figures 4A, 4B, and S4A). In contrast,
active forms of Rho and JNK (guanosine triphosphate [GTP]-
bound Rho and phosphorylated JNK) were increased only at
the EB stage (Figures 4C, 4D, and S4C). These data are consis-
tent with the expression patterns of WNT3 andWNT9B (Figures
3J and S3G). Together, the results suggest that WNT3/b-catenin
signaling is activated predominantly at the ES and NE stages,ryotypically Normal hESC Lines
tes gain of chromosome 17 in BG01V2-E. BG01 (P165), BG03 (P52), BG01V2-E
well-defined colony boundaries. Scale bar, 100 mm.
e. Scale bar, 100 mm.
ANOG (E) in feeder-dependent culture for each hESC line. n = 3. All values in (E)
r-free conditions for each hESC line after 6 days. Percentage of OCT3/4+ cells
1, ***p < 0.001.
ditions for each hESC line after 6 days of bFGF withdrawal. Percentage of cells
awal over 6 days under feeder-free conditions. n = 3. Error bars represent SEM.
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Figure 2. BG01V2 and BG03 Exhibit Highly Efficient mDA Differentiation
(A) Schematic representation of the mDA neuronal differentiation procedure.
(B and C) Phase contrast (B) and expression of OCT3/4 and nestin by immunocytochemistry (C) on day 16 for each hESC line. For BG01V2-E and BG03, rosettes
are interspersed among a layer of cells and are indicated by yellow arrowheads. Scale bar represents 50 mm (B) and 100 mm (C).
(D and E) Relative expression in log2 form (D) and percentages of cells (E) positive for OCT3/4 and nestin at various stages of differentiation. n = 3.
(F) RT-PCR analysis showing expression of genes related to mDA development at various stages of differentiation; +, positive control representing mDA stage of
the BG01 line at day 45.
(G) Percentages of colonies positive for various mDA-relatedmarkers from day 8 to day 16 of differentiation in BG01V2 (-E and -L) and BG03, as denoted by color
legend in (D) and (E). n = 3.
(legend continued on next page)
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while WNT9B/JNK signaling is activated primarily at the EB
stage.
WNT3/b-Catenin Contributes to EnhancedProliferation,
whereas WNT9B/JNK Contributes to Loss of
Pluripotency
To further elucidate the effects of WNT3 and WNT9B in hPSC
lines with trisomy/gains in chromosome 17, we employed (1)
DKK-1 and SP600125, inhibitors of canonical b-catenin signaling
and noncanonical JNK signaling, respectively; (2) lentiviral vec-
tors to overexpress WNTs; or (3) to silence WNT3 and WNT9B
expression through delivery of small hairpin RNAs (shRNAs) at
various stages of mDA differentiation (Figures 4A, 4D, S4B,
S4D, and S7A; Table S6).
First, we explored the roles of WNTs in undifferentiated pro-
liferation and pluripotency in BG01V2, BG03, and CT3. At the
undifferentiated ES stage, DKK-1 administration or WNT3
knockdown, but neither SP600125 nor WNT9B knockdown,
reversed the enhanced proliferation of these lines, indicated
by fewer BrdU-labeled OCT3/4+ cells (Figures 4E and 4F).
DKK-1 also reversed the increased expression of cyclin D1 (Fig-
ure S4E), a downstream target of b-catenin that regulates cell-
cycle progression, to levels comparable to controls. These data
suggest that WNT3/b-catenin signaling is involved in the
enhanced proliferation of BG01V2, BG03, and CT3. In addition,
overexpression of WNT3, but not WNT9B, in CT2 increased the
percentage of BrdU-labeled OCT3/4+ cells (Figure 4G), further
evidence that WNT3 amplification can enhance proliferation
of hPSCs.
Conversely, accelerated loss of pluripotency in BG01V2,
BG03, and CT3 following bFGF withdrawal was reversed
by SP600125 treatment or WNT9B knockdown, but not by
DKK-1 administration or WNT3 knockdown, as indicated by
increased percentages of OCT3/4+ cells (Figures 4H and 4I).
SP600125 also increased expression of OCT3/4 and NANOG
(Figure S4F), after bFGF withdrawal, to levels similar to controls.
These results are concordant with the increased expression of
WNT9B, but notWNT3, in BG01V2 and BG03 6 days after with-
drawal of bFGF (Figure 4J). The results are also consistent with
the activation of JNK, but not b-catenin, seen on day 6 (Figures
4K and 4L). JNK activation peaked earlier in BG01V2 than in
BG03 (Figure 4L) and was lowered by SP600125 to control
levels (Figure 4M). Together, these results indicate that
WNT9B/JNK signaling accelerates the loss of pluripotency in
BG01V2, BG03, and CT3 following bFGF withdrawal. Overex-
pression of WNT9B, but not WNT3, in CT2 decreased the per-
centage of OCT3/4+ cells after bFGF withdrawal, suggesting
that WNT9B amplification can accelerate ES differentiation
(Figure 4N).(H) Expression of LMX1A and nestin by immunocytochemistry at day 16 for BG0
100 mm.
(I) Percentage of LMX1A+ rosettes among total nestin+ rosettes per colony. n = 3
(J) Percentage of LMX1A+ cells among total nestin+ cells in LMX1A+ rosettes. n =
(K) Expression of TH and TUJ1 by immunocytochemistry at day 16 for BG01V2-E
(L and M) Percentages of TUJ1+ cells (L) and cells positive for both TH and TUJ1
Error bars represent SEM. *p < 0.05, **p < 0.01. hPSC, human pluripotent stem
progenitor, mDA, midbrain dopaminergic neuron.
CWNT9B/JNK Promotes mDA Differentiation through
Enhanced Loss of Pluripotency
To investigate the roles of WNTs in mDA differentiation in hPSC
lines with chromosome 17 abnormalities, the overall 16-day
mDA differentiation process was subdivided into total (days 0–
16), EB (days 0–6), and NE (days 6–16) epochs. Interestingly,
SP600125 treatment during either the total or EB epoch, but
not NE, increased expression of OCT3/4 and decreased ex-
pression of nestin and other mDA neuronal markers at day 16
(Figure 5A). These results implicate WNT9B/JNK in early mDA
differentiation and are consistent with the enhanced WNT9B
expression and activation of WNT9B/JNK signaling primarily at
the EB stage (Figures 3J, 4D, S3G, and S4C).
The disruption of mDA differentiation by administration of
SP600125 during the EB epoch could be due either to enhanced
pluripotency or to nonectodermal germ layer differentiation. At
day 8, after EBs have adhered and flattened, SP600125 admin-
istration or WNT9B knockdown produced an increase in OCT3/
4+ cells and a decrease in markers for all three germ layer line-
ages, including nestin, SOX17, and Brachyury (T) (Figures 5B–
5D). These data indicate that blockage of WNT9B/JNK during
the EB stage interrupts hPSC departure from pluripotency,
consistent with previous pluripotency assays (Figures 4H, 4I,
and S4F). Therefore, in chromosome 17-abnormal hPSC lines,
WNT9B/JNK enhances departure of hPSCs from pluripotency,
leading to an increase in neuroectodermal precursors that will
later adopt an mDA fate at the NE stage.
WNT3/b-Catenin Promotes Expansion of NE Cells,
Neuronal Induction, and mDA Differentiation
We next studied the role of WNT3/b-catenin during mDA differ-
entiation in hPSC lines with amplified WNTs. In contrast to
SP600125, DKK-1 treatment did not significantly alter OCT3/4
expression (Figure 6A), suggesting that WNT3/b-catenin is not
involved in the regulation of pluripotency. However, DKK-1 treat-
ment during either total or NE epochs, but not during the EB
epoch, decreased the expression of all mDAmarkers (Figure 6A).
ThusWNT3/b-catenin is involved in latemDA differentiation. This
finding is consistent with the enhanced WNT3 expression and
activation of WNT3/b-catenin signaling primarily at the NE stage
in BG01V2, BG03, and CT3 (Figures 3J, 4A, S3G, and S4A).
During the NE stage, DKK-1 treatment increased nestin
expression (Figure 6A), either due to increased NE cell survival
or proliferation or due to reduced NE cell differentiation. We ruled
out an effect on cell survival by quantifying percentages of nes-
tin+ cells labeled by TUNEL (Figure S5A). NE cell proliferation
was further examined by studying BrdU-labeled nestin+ cells
(10 mM, 1 hr exposure at the end of culture) at day 10 and day
16, when NE proliferation was either predominant (day 10) or1V2-E and BG03 and at day 31 for the remaining lines. Scale bar represents
.
3.
and BG03 and at day 45 for the remaining lines. Scale bar represents 100 mm.
(M) among total cells. n = 3.
cell; EB, embryoid body; NE, neuroepithelial; mDP, midbrain dopaminergic
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Figure 3. The WNT3/WNT9B Gene Cluster Is Amplified in BG01V2 and BG03
(A) A priori list of genes potentially related to mDA neuronal differentiation on chromosome 17.
(B) PCA analysis of CNV and SNP probes located on chromosome 17, indicating overall contribution of each principal component to the overall variance in the
dataset obtained from three distinct passage numbers for BG01, 02, 03, and 01V2 (-E and –L) and one passage number for ES02 and 04.
(legend continued on next page)
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greatly decreasing (day 16) (Figure 6B). At day 10, but not at day
16, DKK-1 administration or WNT3 knockdown decreased cell
proliferation, and DKK1 decreased cyclin D1 expression (Figures
6C–6E and S5B). Thus, the DKK-1-mediated increase in nestin
expression at day 16 was not linked to enhanced proliferation
of NE cells.
We then determined whether DKK-1 administration or WNT3
knockdown influences neuronal fate. As shown in Figures 2F
and 2G, neuronal differentiation began around days 12 to 14 in
BG01V2 and BG03. We therefore examined the effect of DKK-
1 treatment or WNT3 knockdown on neurogenesis during late
NE (days 12 to 16) in BG01V2, BG03, and CT3. Percentages of
BrdU-labeled (1 mM, 24 hr exposure from days 14 to 15) Tuj1+
cells were decreased by DKK-1 administration or knockdown
of WNT3 (Figures 6F–6H), signifying that WNT3/b-catenin is
involved in neurogenesis during the later NE period. Taken
together, these data explain the seemingly paradoxical observa-
tion that blockade of theWNT3/b-catenin pathway in early NE (at
day 10) reduced nestin+ cell populations by decreasing NE cell
proliferation while blocking the pathway during a later NE period
interrupted neurogenesis, thereby causing an accumulation of
NE cells and an increase in nestin expression (Figure 6A).
LMX1A is essential for mDA differentiation of hESCs (Cai et al.,
2009). In mouse ESCs (mESCs), Lmx1A expression is upre-
gulated by WNT/b-catenin signaling and coordinates several
downstream transcription factors including Msx1, Nurr1, and
Pitx3 to induce themDAphenotype (Chung et al., 2009). To study
whether LMX1A was also upregulated by WNT3 through b-cate-
nin in chromosome 17-abnormal lines, we examined LMX1A
expression following DKK-1 treatment during late NE (days 12–
16) and observed a dose-dependent decrease in LMX1A ex-
pression in BGO1V2 and BGO3 (Figure S5C). This finding was
confirmed using another WNT signaling inhibitor, sFRP2 (Fig-
ure S5C), which binds to WNT directly, as opposed to DKK-1,
which binds to the WNT receptor complex (Kawano and Kypta,
2003), and byWNT3 knockdown in CT3 during late NE (Figure 6I).
In addition, overexpression of WNT3 in CT2 during late NE
increased LMX1A expression (Figure 6J). These data suggest
that WNT3/b-catenin upregulates LMX1A expression during
mDA differentiation in these abnormal hPSC lines. As expected,
blockade of WNT3/b-catenin signaling in those lines by DKK-1
administration or WNT3 knockdown during late NE reduced
the production of LMX1A+ mDPs (Figures 6K–6M) and interrup-
ted mDA development as indicated by reductions in TUJ1+ neu-
rons and TH+ mDA neurons (Figures 6N–6R). Therefore, upregu-
lation of LMX1A through the WNT3/b-catenin pathway during(C) PC2 values derived from the hybridization intensities of DNA samples. A, B, a
(D) The PC2 scores highlight five regions on chromosome 17 that may contrib
represented by a red number on the ideogram (middle diagram). Genes located in
tables. The genes of interest, WNT3 and WNT9B, are located between 41.6 Mb
(E) qPCR analysis of seven genes in different hESC lines: BG01, BG02, BG03, and
fold changes with respect to BG01. Horizontal lines represent the mean value fo
(F) Schematic representation of probe numbers and locations for the 17q21.31 t
(G and H) qPCR analysis of copy-number variations in this region in additional hES
changes with respect to CT2 (black line).
(I) Schematic showing extent of the amplified regions (above 1.5 fold change) fo
(J) Relative expression of genes at different stages of mDA differentiation. Values
bars represent SEM. Cell line labels for (E) and (J) are shown on the right of (J).
Clate NE promotes specification of the mDA fate in BG01V2,
BG03, and CT3.
Other Possible Factors Contributing to Rapid mDA
Differentiation in hPSC Lines with Chromosome 17
Abnormalities
To assess the possible involvement of other pathways in mDA
differentiation of chromosome 17 abnormal hPSC lines, we first
examined the roles of FGF8 and SHH in their rapid mDA differ-
entiation. The mDA differentiation protocol (Yan et al., 2005) in-
cludes addition of FGF8 from days 10 to 16 to promote ventral
midbrain patterning, yet FGF8 withdrawal or treatment with a
SHH inhibitor (cyclopamine) from days 0 to 16 did not alter
expression of OCT3/4, nestin, or mDA neuronal markers (Fig-
ure S5D). Moreover, expression of FGF8 and SHH at different
mDA stages did not significantly differ between control and
abnormal lines (Figures 3J and S3G), suggesting that neither
FGF8 nor SHH signaling was involved in the rapid mDA differen-
tiation of hPSCs with chromosome 17 abnormalities.
To exclude the possibility that WNT3 andWNT9B involvement
in mDA differentiation was selective for the particular differentia-
tion protocol used for this study, we used a directed, non-EB-
based, neural differentiation protocol based on dual SMAD inhi-
bition (Chambers et al., 2009). This procedure induces neural
progenitor cells from ES cells in 7–10 days, as well as inducing
an mDA fate by day 19 with the addition of SHH at day 5 and
FGF8 at days 9 through 12. To examine mDA induction in the
abnormal lines, we adopted a 10-day (NE) differentiation period
(Figure S6A), excluding SHH and FGF8, based on the results of
our original protocol, which showed that mDA induction could
be obtained in the abnormal lines by the NE stage.
Gene expression analysis at day 5 indicated that CT3 rapidly
lost OCT3/4, with a simultaneous increase in nestin expression
(Figure S6B). Therefore, CT3 shows more efficient neural pro-
genitor conversion from the ES stage. WNT9B knockdown, but
not WNT3 knockdown, blocked OCT3/4 downregulation and
nestin upregulation, indicating that WNT9B promotes NE induc-
tion through enhanced loss of pluripotency in CT3 (Figure S6C).
No change in the expression of SOX17 or T was caused by
WNT9B knockdown (Figure S6C), possibly due to dual SMAD in-
hibitor-mediated suppression of SOX17 and T (Chambers et al.,
2009). However, CT3 failed to show efficient mDA induction on
day 10 (Figure S6D), and measurement of WNT activity during
10-day differentiation indicated that only WNT9B/JNK signaling
was activated in CT3, as compared to CT2 (Figures S6F and
S6G). Interestingly, adding bFGF to CT3 cultures through daysnd C represent different passage numbers (see Figure S3C).
ute to the phenotypic differences. Each of the five regions is enlarged and
each amplified region were obtained using NCBI Build 36.3 and are listed in the
and 42.3 Mb and are highlighted in red.
BG01V2 (-E and -L) (n = 3) and ES02 and ES04 (n = 1). Values are expressed as
r each data set. *p < 0.05, **p < 0.01, ***p < 0.001.
arget region.
C (G) and hiPSC (H) lines using designed probes. Values are expressed as fold
r the indicated hESC and hiPSC lines. NCBI Build 37.5 used for (F)–(I).
are expressed as fold changes, in log2 form, with respect to BG01. n = 3. Error
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Figure 4. WNT3/b-Catenin andWNT9B/JNK Signaling Are Differentially Activated at Various Stages of mDADifferentiation and Play a Role in
Undifferentiated Proliferation and Pluripotency
(A) Immunoblot of dephosphorylated (active) b-catenin levels at various stages of mDA differentiation in the presence or absence of 500 ng/ml DKK-1. ES
represents 6 days of feeder-free culture supplemented with bFGF, EB represents days 0–6 of differentiation, and NE represents days 6–16 of differentiation. ES
(n = 4), EB (n = 3), NE (n = 4).
(B) Immunoblot showing dephosphorylated (active) b-catenin levels in BG01V2 at various stages of mDA differentiation. Values were expressed as a ratio to
BG01V2 at the ES stage (dashed line). ES (n = 4), EB (n = 3), NE (n = 4).
(C) Immunoblot of active Rho levels in hESC lines at various stages of mDA differentiation. Addition of GTP to activate Rho in BG01was used as a positive control.
ES, EB, NE (n = 3).
(legend continued on next page)
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4–10, as per our original protocol, resulted in a switch from non-
canonical to canonical WNT signaling (Figures S6F and S6G) and
resulted in substantial mDA induction on day 10 (Figures S6D
and S6E).
Knockdown ofWNT3, but notWNT9B, during days 4–10 effec-
tively inhibited bFGF-induced mDA induction in CT3 (Figures
S6D and S6E), suggesting a role of WNT3 in mDA induction.
This was confirmed by inducing mDA differentiation in CT2 by
overexpression of WNT3 from days 4 to 10, with bFGF included
(Figure S6H). Complete mDA differentiation with FOXA2 expres-
sion could be achieved at day 10 in CT3 with the addition of both
bFGF and SHH through days 4–10 (Figure S6I). These results are
consistent with our previous findings suggesting that WNT9B/
JNK and WNT3/b-catenin perform independent, distinct roles
at each stage of differentiation to achieve potent mDA neuronal
conversion in hPSC lines with amplified WNT3/WNT9B.
bFGF Determines whether WNT3/b-Catenin or
WNT9B/JNK Acts to Regulate Distinct Processes of
mDA Differentiation of hPSCs
The expression patterns of WNT3 and WNT9B during mDA dif-
ferentiation (Figures 3J and S3G) may contribute to mechanisms
whereby WNT3/WNT9B amplification in hPSCs can influence
both undifferentiated proliferation and differentiation. Due to
the correlation between WNT3/b-catenin activation and the
presence of bFGF, WNT9B/JNK activation when bFGF is absent
(Figures S6F andS6G), and because it has been shown thatWNT
and FGF pathways cooperate in various cellular processes,
including pluripotency (Ding et al., 2010), we examined the
signaling crosstalk between WNTs and bFGF in mDA differenti-
ation in hPSCs with amplified WNT3/WNT9B.
We examined whether phosphatidylinositol 3-kinase (PI3K)/
AKT and mitogen-activated protein kinase (MAPK)/ERK path-
ways, which are activated by bFGF in hPSCs (Ding et al.,
2010), can be activated by bFGF in hPSCs with WNT3/WNT9B
amplification. In CT3 starved for 24 hr, by omission of KSR and
bFGF, both pathways were activated by bFGF (Figure 7A), sug-
gesting that both PI3K/AKT andMAPK/ERK are downstream tar-
gets of bFGF signaling in abnormal hPSCs. Next, we determined
if these two pathways are involved in enhanced undifferentiated(D) Immunoblot showing phosphorylated JNK (P-JNK) levels in hESC lines at var
positive control for the ES and NE stages. For the EB stage, BG01V2 and BG03
(E–G) Percentage of OCT3/4+ cells incorporating BrdU for BG01V2 and BG03 trea
or WNT9B knockdown in CT3 (F), or for lentivirus-mediated WNT3 or WNT9B o
(dashed line) was used for comparison in (E). n = 3.
(H and I) Quantification of percentages of cells remaining OCT3/4+ after 6 days of b
SP600125 (H) or for lentivirus-mediatedWNT3 orWNT9B knockdown in CT3 (I), un
n = 3.
(J) Relative expression ofWNT3 andWNT9B in BG01V2 and BG03 under feeder-f
changes with respect to BG01 (dashed line) at day 6. n = 4.
(K) Immunoblot of dephosphorylated (active) b-catenin levels on day 6 under feed
the presence of bFGF was used as a positive control. n = 4.
(L andM) Immunoblot of P-JNK in BG01V2 and BG03 under feeder-free condition
presence or absence of 10 mM SP600125 on day 6 (M). BG01 was used for com
(N) Quantification of percentages of cells remaining OCT3/4+ after 6 days of bFG
under feeder-free conditions. n = 3. All immunoblot values were normalized to inte
ratios to BG01 (A, C, D, J), to BG01V2 at the ES stage (B, dashed line), to BG01 at
for BG03 and BG01V2 in (E), (H), and (J) are represented by + and *, respectively
Cproliferation. Using U0126 or LY294002 to block ERK or AKT ac-
tivities respectively (Figure 7A), we found that inhibition of ERK,
but not AKT, significantly reduced proliferation rate and cyclin
D1 expression in CT3, though neither of these pathways seemed
to be involved in normal hPSC line proliferation (Figures 7B and
7C). These data indicate that the bFGF/ERK pathway, but not
bFGF/AKT, is involved in the enhanced proliferation of undiffer-
entiated hPSCs caused by amplification of WNT3/WNT9B.
We next asked how bFGF/ERK cooperates with WNTs to
enhance proliferation in the abnormal lines. Activity of b-catenin
was significantly decreased after U0126 treatment in CT3, but
not in normal hPSCs, suggesting that MAPK/ERK is involved in
enhanced b-catenin activity in hPSC lines with amplified WNTs
(Figure 7D). It has been suggested that FGF signaling through
ERK phosphorylates LRP6, a WNT coreceptor for the canonical
signaling pathway, at PPPS/TP motifs (Krejci et al., 2012),
creating additional high-affinity binding sites for ASIN1/GSK3,
causing ASIN1/GSK3 to be sequestered from the b-catenin
destruction complex, thereby increasing b-catenin stability and
amplifying canonical WNT signaling. Therefore, we examined
whether MAPK/ERK signaling is implicated in the phosphoryla-
tion of LRP6 at Ser1490 in a PPPS/TP motif. U0126 significantly
decreased phosphorylation of LRP6 in CT3 cells (Figure 7E). In
addition, WNT3 knockdown, but not WNT9B knockdown,
decreased LRP6 phosphorylation (Figure 7F). These data sug-
gest that bFGF signaling through MAPK/ERK amplifies the
canonical WNT signaling pathway by phosphorylating LRP6, re-
sulting in enhanced undifferentiated proliferation of hPSCs with
amplified WNTs.
Conversely, when bFGF was withdrawn, phosphorylation of
ERK and LPR6 and activity of b-catenin gradually decreased, fol-
lowed by an increase in activity of JNK in CT3 (Figures 7G and
7H). It has been suggested that noncanonical WNT antagonizes
the canonical WNT pathway through upregulation of SIAH2,
which promotes b-catenin degradation (Topol et al., 2003). We
found that SIAH2 was upregulated following bFGF withdrawal
and that this upregulation was reversed by knockdown of
WNT9B, but not WNT3, in CT3 (Figures 7H and 7I). These data
suggest that in hPSCs withWNT3/WNT9B amplification, without
bFGF/ERK/LPR6 to stabilize and amplify the WNT/b-cateninious stages of mDA differentiation. H202 (10
3M, 1 hr) in BG01 was used as a
were treated with 10 mM SP600125. ES, EB, NE (n = 4).
ted with 500 ng/ml DKK-1 or 10 mMSP600125 (E), for lentivirus-mediatedWNT3
verexpression in CT2 (G) over 6 days in feeder-free culture with bFGF. BG01
FGF withdrawal for BG01V2 and BG03 treated with 500 ng/ml DKK-1 or 10 mM
der feeder-free conditions. BG01 (dashed line) was used for comparison in (H).
ree conditions after 6 days of bFGF withdrawal. All values are expressed as fold
er-free conditions after 6 days of bFGF withdrawal. BG01V2 at the ES stage in
s at various stages over a 6-day period following bFGF withdrawal (L) and in the
parison. n = 3.
F withdrawal for lentivirus-mediated WNT3 or WNT9B overexpression in CT2
rnal control (GAPDH [A, B, K], total Rho [C], or JNK [D, L, M]) and expressed as
day 2 (L), or to control (M). SP = SP600125. Error bars represent SEM. p values
. +p and *p < 0.05; **p < 0.01; +++p and ***p < 0.001.
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Figure 5. WNT9B/JNK Signaling Regulates
mDA Differentiation during Early NE
(A) Relative expression of genes involved in mDA
differentiation following treatment with 10 mM
SP600125 every other day during three distinct
periods: total (days 0–16), EB (days 0–6), and NE
(days 6–16). All BG01V2 and BG03 values are ex-
pressed as fold changeswith respect to the control
condition, i.e., without SP600125 (dashed line).
n = 3.
(B) Expression of germ layer markers (nestin,
SOX17, and T) by immunocytochemistry at day 8
for BG01V2 and BG03 in the presence or absence
of 10 mM SP600125. Scale bar represents 100 mm.
(C and D) Percentages of cells positive for OCT3/4,
nestin, SOX17, and T at day 8 for BG01V2 and
BG03 in the presence or absence of 10 mM
SP600125 or for CT3 after control or WNT9B
shRNA lentivirus-mediated infection. n = 3. The
dashed line represents BG01 in (C). Error bars
represent SEM. p values for BG03 and BG01V2,
with respect to the control condition, are repre-
sented by + and *, respectively. +p and *p < 0.05;
++p and **p < 0.01; ***p < 0.001.
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Figure 6. WNT3/b-Catenin Regulates mDA Differentiation during Late NE
(A) Relative expression of genes involved in mDA differentiation following treatment with 500 ng/ml DKK-1 every other day during the total (days 0–16), EB (days
0–6), and NE (days 6–16) differentiation epochs. BG01V2 and BG03 values are expressed as fold changes with respect to the control condition, i.e., in the
absence of DKK-1 (dashed line). n = 3.
(B) Percentage of BrdU-labeled nestin+ cells from day 8 to day 16. n = 3.
(C and D) Expression of BrdU and nestin (C) by immunocytochemistry for BG01V2 and BG03 at day 10 and day 16 in presence or absence of DKK-1. Cells were
treated with DKK-1 (500 ng/ml) for 2 days prior to the end of culture. Corresponding BrdU-labeled nestin+ cellular percentages are shown in (D). Scale bar
represents 50 mm. n = 3.
(E) BrdU-labeled nestin+ cellular percentages for lentivirus-mediated WNT3 knockdown (4 days prior to end of culture) in CT3 at days 10 and 16. n = 3.
(legend continued on next page)
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pathway, noncanonical WNT becomes dominant due to upregu-
lation of SIAH2 and contributes to enhanced loss of pluripotency
through JNK signaling.
Finally, we studied the crosstalk between WNTs and bFGF in
mDA differentiation using the dual SMAD inhibition protocol to
avoid the complexities of EB formation. As discussed above,
treatment with bFGF through days 4–10 switched noncano-
nical to canonical WNT signaling and induced mDA differ-
entiation (Figures S6D, S6F, and S6G). We also found that
phosphorylation of ERK and LRP6, and activity of b-catenin,
were gradually increased during days 4–10 in the presence
of bFGF in CT3 (Figure 7J) and knockdown of WNT3, but not
WNT9B, inhibited b-catenin activation (Figure 7K). These
data suggest that bFGF signaling through ERK/LPR6 enables
canonical WNT signaling to become dominant by stabilizing
and amplifying canonical WNT signaling. In addition, temporal
gene expression analysis revealed that LMX1A, a downstream
target of canonical WNT signaling, was increased by bFGF
treatment from day 4 to day 10 in CT3 (Figure 7L), and knock-
down of WNT3, but not WNT9B, induced a substantial loss of
LMX1A and expression of its downstream mDA-specific tran-
scription factors (Figure 7M). These data indicate that bFGF
stabilizes canonical WNT signaling, contributing to efficient
mDA induction through upregulation of LMX1A in chromosome
17-abnormal lines, and reveal the role of bFGF in the interplay
of WNT3 and WNT9B signaling at each stage of differentiation
(Figure 7N).
DISCUSSION
Our study has identified amplification of theWNT3/WNT9B clus-
ter located at the border between 17q21.31 and 17q21.32 as a
major contributor to several important phenotypic properties of
hPSCs: enhanced proliferation in the undifferentiated stage,
accelerated loss of pluripotency after withdrawal of bFGF, and
rapid mDA differentiation. Trisomy 17 has been repeatedly
observed in hESC cultures (Baker et al., 2007), possibly due to
selective pressure exerted by culture conditions. Even in the
absence of trisomy 17, however, gains of small regions on chro-
mosome 17, including 17q21.31, seem to be fairly common in
hESCs (Na¨rva¨ et al., 2010).
Whereas CNVs at 17q21.31 occur in phenotypically normal
humans (Table S3), genetic anomalies at 17q21.31 have been
linked to Parkinson’s disease, disorders of neural development
(Spencer et al., 2011; Grisart et al., 2009), and autism (Girirajan
et al., 2011). Understanding the functions of the WNT3-WNT9B(F andG) Expression of BrdU and TUJ1 (F) by immunocytochemistry for BG01V2 a
and TUJ1+ cells are shown in (G). Scale bar represents 50 mm, n = 3.
(H) Relative percentage of BrdU-labeled TUJ1 cells for lentivirus-mediated WNT
(I and J) Relative expression of LMX1A for lentivirus-mediated WNT3 knockdown
(K and L) Expression of LMX1A (K) by immunocytochemistry for BG01V2 and BG0
are shown in (L). Scale bar represents 100 mm. n = 3.
(M) Percentages of LMX1A+ cells for lentivirus-mediated WNT3 knockdown (day
(N–P) Expression of TUJ1 and TH (N) by immunocytochemistry for BG01V2 and B
and TH+ and TUJ1+ (P) cells are shown. Scale bar represents 100 mm. n = 3.
(Q and R) Percentages of TUJ1+ (Q) and TH+ (R) cells for lentivirus-mediated WN
For (F), (G), (K), (L), and (N)–(P), cells were treated with DKK-1 for 4 days prior to th
by + and for BG01V2 and CT3 are represented by *. +p and *p < 0.05; ++p and **
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of these disorders.
We performed preliminary experiments to examine the
neuronal differentiation ability for different hPSC lines using
the protocol in Figure 2A but withdrawing all of the trophic fac-
tors, such as bFGF and FGF8. At day 16, BG01, BG02, ES02,
and ES04 exhibited a dorsal forebrain neural progenitor cell
fate, expressing the anterior telencephalic transcription factors
BF1 and OTX2 and the dorsal forebrain marker PAX6. For the
abnormal lines including BG01V2 and BG03, however, most col-
onies exhibited abundant projections and a neuronal phenotype.
Small percentages of the neural progenitors in BG01V2 and
BG03 expressed PAX6, but most expressed LMX1A. In addition,
these progenitors did not express the hindbrain/spinal cord
marker HOXB4 or the ventral telencephalic marker NKX2.1.
We further examined the specific types of neurons generated
from BG01V2 and BG03 differentiation and found a significant
induction of TH+ neurons, with only a small percentage of gluta-
mate neurons and no GABA or motor neuron marker-HB9-ex-
pressing neurons. These data indicate that normal hPSC lines
have a natural tendency to differentiate to a dorsal telenceph-
alon phenotype, but the abnormal lines examined here have a
tendency to become mDA neurons. Due to these preliminary
data, we focused on mDA differentiation for hPSCs with ampli-
fication of 17q21.31/WNT3-WNT9B. Figure S7B provides addi-
tional data, with statistics, regarding the mDA differentiation of
11 hPSC lines: seven normal hPSC lines (BG01, BG02, ES02,
ES04, H7, H14, and CT2) and four abnormal hPSC lines
(BG03, BG01V2-E, CT3, and H1) (with similar genotype as
shown in Figure 3I) using the protocol shown in Figure 2A in
the absence of trophic factors. These data show that at day
16, the abnormal lines produced significantly more DA neurons
than the normal lines.
It is remarkable that BG01V2, BG03, and CT3 display more
rapid departure from pluripotency and differentiation despite ex-
hibiting enhanced proliferation in the undifferentiated state. The
increase in DNA encoding WNT3 and WNT9B was modest yet
consistent with the presence of additional copies of these genes.
Increases in mRNA were much greater, supporting altered regu-
lation as well as altered copy number (Figures 3D, 3E, and 3J;
Table S2). The greater enhancement of WNT3 and WNT9B
expression than DNA might be caused by genetic alterations re-
sulting in greater enhancer or promoter efficiency, epigenetic
modifications such as differential methylation of the additional
DNA copies, or other unknown regulatorymechanisms. Our find-
ings emphasize the importance of elucidating cellular functionalnd BG03 at day 16 in the presence or absence of DKK-1. Percentages of BrdU+
3 knockdown (days 12–16) in CT3. n = 6.
in CT3 (I) and WNT3 overexpression in CT2 (J) from days 12 to 16. n = 3.
3 at day 16 in the presence or absence of DKK-1. Percentages of LMX1A+ cells
s 12–16) in CT3. n = 3.
G03 at day 16 in the presence or absence of DKK-1. Percentages of TUJ1+ (O)
T3 knockdown (days 12–16) in CT3. n = 3 (Q), n = 6 (R).
e end of culture. Error bars represent SEM. p values for BG03 are represented
p < 0.01; +++p and ***p < 0.001.
Figure 7. Molecular Mechanisms Involved in WNT3/WNT9B-Regulated Proliferation in the Undifferentiated State and mDA Differentiation
(A) Immunoblot showing phosphorylated ERK (P-ERK) and phosphorylated AKT (P-AKT) levels in hESC lines, with KSR and bFGF withdrawn overnight, treated
with the ERK inhibitor U0126 or the AKT inhibitor LY294002 1 hr prior to adding 20 ng/ml bFGF for 30 min.
(legend continued on next page)
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changes in hPSCs caused by even modest-sized genomic
changes.
Epigenetic factors are important regulators in neural differ-
entiation from hPSCs. Kim et al. (2011) showed a neural dif-
ferentiation bias based on expression of miR-371-3. By using
Agilent-016436 Human miRNA Microarray 1.0 G4472A (miRNA
ID version), Figure S7C show the differential expression of
miR-371 among eight hPSC lines, including six normal hPSC
lines (BG01, BG02, ES02, ES04, H7, and H14) and two abnormal
lines (BG03 and H1). Although there are differences in miR-371
between the BG lines and ES lines as compared to the H lines,
these are not correlated with the overall functional variance
among our hPSC lines. We also did not find other significant cor-
relations for epigenetic factors, microRNA (miRNA) or methyl-
ation, and the functional variance among these hPSC lines based
on the NIH Human Pluripotent Stem Cell Database, compiled by
the NIH stem cell unit (Mallon et al., 2013;Mallon et al., 2014) with
whomwe collaborated. While it is certainly true that multiple fac-
tors, such as CNVs, SNPs, miRNA, and methylation can influ-
ence the differentiation of hPSCs, here we have focused on
just one such factor, 17q21.31/WNT3-WNT9B amplification;
however, we do not mean to imply that this is the only reason
that hPSC lines differ from one another.
A number of previous studies have identified roles of WNT1,
WNT3A, and WNT5A in mDA differentiation (Castelo-Branco
et al., 2003; Chung et al., 2009; Kriks et al., 2011). We found
that DKK-1 treatment or WNT3 knockdown during NE downre-
gulates expression of LMX1A, MSX1, NGN2, NURR1, and
PITX3 (Figures 6A and S5E). In hPSCs with amplified WNTs,
enhanced WNT3/b-catenin signaling accelerates mDA specifi-
cation via upregulation of LMX1A, but without FOXA2 expres-
sion. FOXA2 induction could, however, be achieved by addition
of SHH, consistent with reports that both WNT-LMX1A and
SHH-FOXA2 signaling pathways contribute to mDA neuronal dif-
ferentiation (Chung et al., 2009, Kriks et al., 2011).
Furthermore, it has been suggested that WNT5A acts on non-
canonical pathways to increase rodent mDA neuronal differenti-
ation (Castelo-Branco et al., 2003). SinceWNT9B/JNK blockade(B) Percentage of OCT3/4+ cells incorporating BrdU under feeder-free condition
LY294002 over 6 days. n = 3.
(C) Relative expression of cyclin D1 in CT3 in the presence or absence of U0126 or
expressed as fold changes with respect to the control. n = 3.
(D) Immunoblot showing dephosphorylated (active) b-catenin levels in hESC line
bFGF. n = 3.
(E and F) Immunoblot showing phosphorylated LRP6 (P-LRP6) levels in CT3 in th
lentivirus-mediated infection (F), for 6 days of feeder-free culture with bFGF. n =
(G and H) Immunoblot of P-ERK, P-LRP6, and dephosphorylated (active) b-caten
6 days of bFGF withdrawal.
(I) Immunoblot showing SIAH2 levels for lentivirus-mediated WNT3 or WNT9B kno
n = 3.
(J) Immunoblot showing P-ERK, P-LRP6, and dephosphorylated (active) b-catenin
(K) Immunoblot showing dephosphorylated (active) b-catenin levels for lentiviru
inhibition in the presence of bFGF. n = 3.
(L) Relative expression of LMX1A in CT3 during dual-SMAD inhibition in the prese
with respect to CT3 at day 0. n = 3.
(M) Relative expression of LMX1A,MSX1, NGN2, PITX3, and NURR1 for lentivirus
inhibition, in the presence of bFGF. n = 3.
(N) Schematic illustrating the roles of WNT3 and WNT9B in mDA differentiation
represent SEM. *p < 0.05; **p < 0.01; ***p < 0.01.
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WNT5A and WNT9B may act via different noncanonical path-
ways. In this study, we identify a role for noncanonical WNT
signaling during early mDA differentiation, suggesting that
variousWNT-regulated pathways can work cooperatively in pro-
moting mDA differentiation.
Due to activity of the b-catenin destruction complex, cyto-
plasmic b-catenin levels are normally low. WNT-mediated phos-
phorylation of mature (transmembrane) LRP6 occurs when the
signalosome complex is formed by assembly of WNT and
LRP6. This is in contrast to ERK, which is able to phosphorylate
both mature and immature (intracellular) LRP6. ERK-phosphor-
ylated LRP6 is able to divert a minor amount of ASIN1/GSK3
from the b-catenin destruction complex; however, this is not suf-
ficient to stabilize b-catenin on its own. When WNT is present,
ERK-phosphorylated LRP6 is able to dramatically contribute to
stabilizing b-catenin and amplifying canonical WNT signaling
(Krejci et al., 2012). Our findings also indicate that, without
bFGF, abnormal hPSCs with amplified WNTs exhibited only
limited activity of b-catenin, no different from normal hPSCs.
However, activity of b-catenin is enhanced by bFGF, through
phosphorylation of LRP6 at PPPS/TPmotifs. Once bFGF is with-
drawn, without the subsequent ERK/LPR6 pathway to stabilize
b-catenin, noncanonical WNT becomes the dominant mode of
WNT signaling.
Our results demonstrate that bFGF regulates whether WNT3/
b-catenin or WNT9B/JNK is dominant in regulating distinct pro-
cesses of mDA differentiation. WNT9B, acting through a non-
canonical pathway, guides hPSCs away from pluripotency and
toward neuroectodermal differentiation. WNT3 accelerates un-
differentiated hPSC proliferation, furthers expansion of neuroec-
todermal cells, and directs them to an mDA fate (Figure 7N).
Although WNT3 and WNT9B are not known to be involved in
normal human midbrain development, their role in orchestrating
mDA differentiation of hPSCs under conditions of 17q21.31-
17q21.32 amplification suggests that CNVs in this region have
the capacity to cause profound alterations in neural differentia-
tion and development.s for each hESC line with bFGF and in the presence or absence of U0126 or
LY294002 cultured in feeder-free conditionswith bFGF for 6 days. All values are
s in the presence or absence of U0126 over 6 days in feeder-free culture with
e presence or absence of U0126 (E), or for control, WNT3, or WNT9B shRNA
3.
in (G) and P-JNK, SIAH2 (H) levels for CT3 under feeder-free conditions during
ckdown in CT3 under feeder-free conditions after 6 days of bFGF withdrawal.
levels in CT3 during dual-SMAD inhibition in the presence or absence of bFGF.
s-mediated WNT3 or WNT9B knockdown (days 4–10) in CT3 for dual-SMAD
nce or absence of bFGF. Values are expressed as fold changes, in log2 form,
-mediated WNT3 or WNT9B knockdown (days 4–10) in CT3, using dual-SMAD
in human pluripotent stem cells with WNT3/WNT9B amplification. Error bars
EXPERIMENTAL PROCEDURES
hESC Culture
The hESC lines BG01 (passage 163 [P163]–P187), BG02 (P39–P69), and BG03
(P47–P64), provided by BresaGen; BG01V2-E (P32–P54) and BG01V2-L (P78–
P96), derived from BG01 (Vazin et al., 2008); ES02 (P45–P 58) and ES04 (P65–
P74), provided by ES Cell International (Singapore); H1 (P40–P44), H7 (P43–
P45), and H14 (P40–P58), provided by WiCell Research Institute; and CT2
(P90–P109) and CT3 (P27–P55), provided by University of Connecticut Stem
Cell Core, were cultured as previously described (Vazin et al., 2008). For
more details, see the Supplemental Experimental Procedures.
SNP Array 6.0 and Analytical Methods
DNAwas extracted from undifferentiated hESC lines and quantitated and gen-
otyped using Affymetrix 6.0 microarrays to the manufacturer’s instructions.
Hybridization intensities for all chromosome 17 SNP and CNV probes were
subjected to PCAs as described in the Supplemental Experimental Proce-
dures. Quantification of cell numbers, proteins, RNA, and DNA was performed
using immunocytochemistry, western blotting, RT-PCR, qRT-PCR, and q PCR
using standard methods as described in the Supplemental Experimental Pro-
cedures and primers as listed in Tables S4 and S5.
Statistical Analysis
Data are shown as means ± SEM. Means were compared by two-tailed t tests
or by one-way ANOVA followed by Tukey’s compromise post hoc test for mul-
tiple comparisons, using GraphPad InStat Version 3 software. The criterion for
statistical significance was p < 0.05.
ACCESSION NUMBERS
The Affymetrix 6.0 microarray data have been deposited to the NCBI GEO un-
der accession number GSE64241.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.12.050.
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